An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...

The about-$1 billion deal could come imminently.

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

Eli Lilly and Company (NYSE:LLY) is one of the best performing pharma stocks in 2025. Eli Lilly and Company (NYSE:LLY) ...

Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.

Dividend growth investing builds long-term wealth for retirement by focusing on companies that consistently increase payouts.

Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese ...

Eli Lilly is considering all these risks and planning accordingly, and doing so years in advance. That's also why the ...

Eli Lilly has the lead in the GLP-1 race, but Novo Nordisk just changed the game.

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Despite Super Bowl rings and big plays, "Manning fatigue" may hurt his case. That would be a shame because Eli was a master ...